Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Hepatology

Volumn 34, Issue 5, 2001, Pages 1035-1040

  Sauleda, Silvia ^a   Juárez, Alberto ^b   Esteban, Juan I ^b   Altisent, Carmen ^b   Ruiz, Isabel ^b   Puig, Lluís ^a   Esteban, Rafael ^b   Guardia, Jaime ^b  

^a Centre de Transfusio i Banc de Teixits   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VIRUS REPLICATION;

EID: 0034762355     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.29130     Document Type: Article

References (28)

1. A multicenter study of viral hepatitis in a United States hemophilia population
2. Hepatitis C antibody profile and viremia prevalence in adults with severe haemophilia
3. Natural history of hepatitis C virus infection in multitransfused hemophiliacs. Effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study
4. The progression of HCV-associated liver disease in a cohort of hemophilic patients
5. The natural history of chronic hepatitis C in haemophiliacs
6. Immunosupression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV
7. Mortality from liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
8. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
9. Hepatitis C virus and human immunodeficiency virus: Clinical issues of coinfection
10. Hepatotoxicity associated with antiretroviral therapy in adults with HIV and role of hepatitis B or C infection
11. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during early phases of combination antiretroviral treatment
12. Hepatitis C virus-associated hepatitis following treatment of HCV infected patients with HIV protease inhibitors: An immune restoration disease?
13. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
14. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
15. Does HIV infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter propective study
16. Ribavirin antagonizes the effect of azidothymidine on HIV replication
17. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: A concentration-dependent interaction
18. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
19. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
20. Rapidly progressive non A non B hepatitis in patients with HIV infection
21. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study
22. Treatment with Interferon plus Ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C
23. Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients
24. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
25. Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in HIV coinfected patients
26. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
27. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin
28. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy